USANA Health Sciences (NYSE:USNA) Releases Quarterly Earnings Results

USANA Health Sciences (NYSE:USNA) released its quarterly earnings results on Tuesday. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.17, FiscalAI reports. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%.The firm had revenue of $250.22 million for the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences updated its FY 2026 guidance to 1.950-2.290 EPS.

USANA Health Sciences Stock Performance

USNA traded up $0.63 during midday trading on Tuesday, hitting $19.19. The stock had a trading volume of 97,344 shares, compared to its average volume of 124,924. The company has a market cap of $354.13 million, a P/E ratio of 34.89, a price-to-earnings-growth ratio of 0.83 and a beta of 0.77. The business has a fifty day moving average of $18.58 and a 200 day moving average of $19.73. USANA Health Sciences has a 1 year low of $16.60 and a 1 year high of $38.32.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, insider Joshua Foukas sold 4,461 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $21.34, for a total value of $95,197.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.82% of the stock is currently owned by corporate insiders.

Institutional Trading of USANA Health Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. National Bank of Canada FI increased its stake in USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after purchasing an additional 1,201 shares during the period. Tower Research Capital LLC TRC increased its stake in USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after purchasing an additional 1,901 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in USANA Health Sciences by 52.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock worth $106,000 after purchasing an additional 1,327 shares during the period. Parallel Advisors LLC increased its stake in USANA Health Sciences by 1,354.3% in the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after purchasing an additional 3,589 shares during the period. Finally, Quantbot Technologies LP increased its stake in USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after purchasing an additional 646 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on USNA shares. Zacks Research cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research note on Friday, March 27th. Finally, Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, USANA Health Sciences has a consensus rating of “Reduce”.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah?based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight?management products and skin?care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical?grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.